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ABSTRACT: Zika virus is a mosquito-transmitted ﬂavivirus that causes
devastating fetal outcomes in the context of maternal infection during
pregnancy. An important target for drugs combatting Zika virus
pathogenicity is NS2B-NS3 protease, which plays an essential role in
hydrolysis and maturation of the ﬂavivirus polyprotein. We identify
hydroxychloroquine, a drug that already has approved uses in pregnancy,
as a possible inhibitor of NS2B-NS3 protease by using a Food and Drug
Administration-approved drug library, molecular docking, and molecular
dynamics simulations. Further, to gain insight into its inhibitory potential
toward NS2B-NS3 protease, we performed enzyme kinetic studies, which
revealed that hydroxychloroquine inhibits protease activity with an
inhibition constant (Ki) of 92.34 ± 11.91 μM. Additionally,
hydroxychloroquine signiﬁcantly decreases Zika virus infection in
placental cells.
■ INTRODUCTION
Zika virus (ZIKV) belongs to the Flavivirus genus and is a
member of the Flaviviridae family. Recent research has revealed
that ZIKV is associated with microcephaly in fetuses1,2 and
neurological disorders such as Guillain-Barre ́ syndrome in
adults.3−5 The rapid spread of this virus, aﬀecting over a
million people6 across multiple continents, has spurred
researchers to search for eﬀective therapeutic intervention. A
broad-spectrum antiviral agent against shared ﬂavivirus
proteins would be especially attractive, given the preponder-
ance of related ﬂavivirus infections (such as dengue and West
Nile viruses) in areas where ZIKV has been most prevalent.
Zika virus is an enveloped virus like other ﬂaviviruses,
encapsulating a single-stranded, positive-sense, RNA genome7
encoding a single polyprotein precursor.8 It is hydrolyzed into
three structural proteins (E, prM/M, and C) and seven
nonstructural proteins (NS1, NS2A, NS2B, NS3, NS4A, NS4B,
and NS5)8−10 by the host and viral proteases.10 Among these
viral and host elements, the viral NS2B-NS3 protease is an
attractive drug target due to its essential role in the virus life
cycle. The crystal structure of NS2B-NS3 protease reveals that
NS2B (only the hydrophilic part was taken in the construct for
crystallographic studies, approximately residues 49−95 of the
full-length NS2B protein constituting ∼130 residues) can be
found in two conformations. In the presence of inhibitor/
substrate, NS2B forms a β-hairpin and lies near the substrate
binding site of NS3 protease, adopting a closed conformation,
but in the absence of inhibitor/substrate, it adopts an open
conformation.11−14 The NS2B-NS3 protease structure with
PDB ID: 5LC013 (hydrophilic part, residues 49−95 of NS2B
fused via a Gly4−Ser−Gly4 linker to the N-terminal of the
NS3 protease) shows NS2B wrapping around NS3 in such a
way that the C-terminal residues of NS2B form a β-hairpin that
contributes to the S2 pocket of the NS3 protease.13−15 As
reported NS2B protein has a high abundance of disorder
promoting residues containing a 37-residue disordered region
(62−98).16,17 The NS2B interaction with NS3 protease
facilitates NS3-mediated cleavage of polyprotein thus, it acts
as an important cofactor for the activity of NS3 protease.18
Generally, disordered proteins lead to functionality only upon
interaction with its binding partner such as transactivation
domain of cMyb, in which cMyb becomes functional only
upon binding its ordered counterpart, KIX.19−22 Together,
NS2B and NS3 form the NS2B-NS3 protease complex that
hydrolyzes the ZIKV polyprotein into functional proteins used
for viral propagation and maturation.11
Viral proteases are considered excellent targets for the
identiﬁcation of potential drug candidates, as protease plays an
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indispensable role in viral replication.23−25 Recently, the
NS2B-NS3 protease has been investigated as a target to
identify potential inhibitors.26−29 Repurposing approved drugs
can be an eﬃcient method to identify drug compounds, which
may be capable of activating or inhibiting new targets.30 This
approach has several advantageous features, including reduced
development time and expense and improved safety.30 In our
study, we screened Food and Drug Administration (FDA)-
approved drugs for their ability to target NS2B-NS3 protease.
We hypothesize that speciﬁc drugs in the library will show
potential to speciﬁcally target NS2B-NS3 protease of ZIKV,
especially given that some drug compounds are already being
used to target NS2B-NS3 protease in other ﬂaviviruses.31−33
Here, we use molecular docking and molecular dynamics
(MD) simulation studies to identify potential drug candidates
from the library based on their predicted ability to target the
active site of NS2B-NS3 protease. Our top hits include
hydroxychloroquine (HCQ), mitoxantrone, miglustat, nadolol,
carteolol, and pindolol. Among these potential candidates,
hydroxychloroquine (HCQ) was shown in a recent study to
have an inhibitory eﬀect on ZIKV in a mouse model of ZIKV
infection during pregnancy.34 Therefore, we pursued further
studies with HCQ and showed that HCQ likely targets the
active site of NS2B-NS3 protease; thus, it may block its ability
to hydrolyze the single polypeptide product of ZIKV into
functional proteins required for ZIKV survival and replication.
Molecular dynamic simulation reveals a signiﬁcant gain in
stability associated with the binding of HCQ to the protease
complex, suggesting a strong binding aﬃnity between HCQ
and the active site of NS2B-NS3 protease. Further, inhibition
assays support the inhibition of NS2B-NS3 protease by HCQ.
Finally, a recent study from our group demonstrated that ZIKV
infection activates the cellular recycling pathway, autophagy,
and that HCQ treatment blocks this activation, leading to a
reduction in ZIKV vertical transmission.34 Also, HCQ shows
antiviral potential in the treatment of dengue virus infection35
by activating the innate immune signaling pathways and
inducing the production of reactive oxygen species. However,
the molecular mechanism of action of HCQ against ZIKV
infection is still unclear. Our work, which describes the
interaction between HCQ and NS2B-NS3 protease in great
detail, may provide a foundation to leverage this compound
and other derivatives in treating patients infected with ZIKV.
■ RESULTS
Virtual Screening of FDA-Approved Drugs. To identify
drug candidates with the potential to inhibit NS2B-NS3
protease, we performed structure-based virtual screening
employing in silico molecular docking techniques. An X-ray
crystal structure of ZIKV NS2B-NS3 protease (PDB ID:
5LC0) was utilized as an input in the docking process. Since
the dipeptide boronic acid acts as an inhibitor of the protease
complex as reported previously,13 we utilized the same binding
site as the active site of NS2B-NS3 protease for docking. After
extra precision (XP) docking, the top 25 compounds were
selected to go through induced ﬁt docking (IFD) protocol.
This docking protocol considers the movement of highly
ﬂexible residues of the NS2B-NS3 protease complex upon
binding of a drug compound at the active site. The IFD scores
of top six compounds, viz., mitoxantrone, hydroxychloroquine
(HCQ), miglustat, nadolol, carteolol, and pindolol, with
NS2B-NS3 protease are shown in Tables 1 and S1.
Table 1. Summary of Induced Fit Docking (IFD) Results of Top-Hit FDA-Approved Drugs Representing Docking Score and
Interacting Amino Acid Residuesa
compound name (ID)
docking score
(kcal/mol) interacting amino acid residues
mitoxantrone (DB01204) −12.785 H-bond: Ser81*, Phe84*, Asp75, Pro131; pi−cation: Tyr161, pi−pi: Tyr161; salt bridge: Asp129, Asp75
hydroxychloroquine
(DB01611)
−10.725 H-bond: Asp83*, Tyr130, Asn152, Gly151; pi−pi: Tyr161, pi−cation: Tyr161; salt bridge: Asp129
aAsterisk (*) for residues that belong to NS2B cofactor.
Figure 1. Molecular interaction of hydroxychloroquine (HCQ) at NS2B-NS3 protease active site. (A) Molecular interaction of HCQ (gray) with
NS2B-NS3 protease (three-dimensional view) by H-bonds (yellow dashed lines), pi−pi interactions (cyan dashed lines), pi−cation interactions
(green dashed lines), and salt bridges (pink dashed lines). (B) Molecular interaction diagram in two-dimensional illustrates interactions between
HCQ and NS2B-NS3 protease by H-bonds (pink arrow), pi−pi interactions (green solid line), pi−cation interactions (red solid line), and salt
bridges (blue-red straight line). [A: asterisks (*) indicate residues that belong to NS2B; B: residues 49−87 of NS2B are denoted 49−87, while
residues 15−167 of NS3 protease are denoted 1015−1167].
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Mitoxantrone and HCQ are associated with the highest
docking scores of −12.785 and −10.725 kcal/mol, respectively
(Table 1), indicating that they have high potential to bind to
NS2B-NS3 protease and to ﬁt in the active site pocket. Both
these compounds, along with miglustat, nadolol, carteolol, and
pindolol, were stabilized at the NS2B-NS3 protease active site
by interactions with key amino acid residues through H-bonds,
pi interactions, and salt bridges (Table S1).
IFD revealed that mitoxantrone was associated with the
highest docking score. Mitoxantrone has a molecular weight
(MW) of 444.5 g/mol, and its interaction with the active site
of NS2B-NS3 protease is established by H-bonds (Ser81 and
Phe84 of NS2B; Asp75 and Pro131 of NS3 protease), pi−pi
interaction (Tyr161 of NS3 protease), a pi−cation interaction
(Tyr161 of NS3 protease), salt bridges (Asp129 and Asp175 of
NS3 protease), and hydrophobic interactions (Trp50, Val72,
Tyr130, Ala132, Tyr150, Val154, and Val155 of NS3 protease)
(Figures S1A and S2A).
Interactions between HCQ (MW: 335.9 g/mol), the second
highest-scoring compound, and protease include H-bonds
involving NS2B (Asp83) and NS3 protease (Tyr130, Gly151,
and Asn152). HCQ also forms a salt bridge (Asp129 of NS3
protease) and pi interactions (pi−pi and pi−cation interactions
with Tyr161 of NS3 protease). Besides, some hydrophobic
amino acid residues (Phe84 of NS2B and Pro131, Ala132,
Tyr150, and Val155 of NS3 protease) contribute to the
interaction between HCQ and the active site of NS2B-NS3
protease (Figure 1). The binding pose of mitoxantrone and
HCQ show that the NS3 component of the protease complex
has a higher number of interacting amino acid residues than
the NS2B cofactor does.
The third-ranking molecule, miglustat (MW: 219.3 g/mol),
interacts with NS3 protease using two H-bonds (Tyr130 and
Ser135), one pi−pi interaction (Tyr161), and one salt bridge
(Ser135). The interaction between miglustat and NS2B-NS3
protease is also established through hydrophobic residues
(Leu128, Pro131, Ala132, Tyr150, and Val162) of NS3
protease (Figures S1B and S2B).
The fourth-ranking molecule is nadolol, (MW: 309.4 g/
mol), which interacts with NS2B through one H-bond
(Asp83) and NS3 protease by ﬁve H-bonds (Tyr130,
Ser135, Asn152, Gly153, and Tyr161) and two pi interactions
(pi−cation at Hie51 and pi−pi at Tyr161). Nadolol is also
stabilized at the active site of NS2B-NS3 protease by
hydrophobic residues of NS2B and NS3 protease (Pro131,
Ala132, Tyr150, Val154, and Val155 of NS3 protease and
Phe84 of NS2B) (Figures S1C and S2C).
Carteolol (MW: 292.4 g/mol), the ﬁfth-ranking drug
compound, interacts with NS3 protease through four H-
bonds (Asp75, Asn152, Tyr161, and Tyr130), two pi
interactions (pi−pi at Tyr161 and pi−cation at Hie51), and
a salt bridge (Asp75) (Figures S1D and S2D). Pindolol (MW:
248.3 g/mol), the sixth-ranking drug compound, shows
interactions with NS3 protease by means of four H-bonds
(Tyr130, Asn152, Gly153, and Tyr161) and one pi−pi
interaction (Tyr161) (Figures S1E and S2E). The interactions
of both carteolol and pindolol with the active site are also
established through hydrophobic residues of NS2B (Phe84)
and NS3 protease (Pro131, Ala132, Tyr150, and Val155).
Molecular Dynamics Simulation. To better understand
the stability of their binding interactions with NS2B-NS3
protease, we subjected these top-scoring six compounds to
molecular dynamics simulation in order to monitor the
conformational changes and dynamic behavior of protein
over the course of a 30 000 ps time period. Changes in the
structural integrity of the protease complex were analyzed by
calculating the root-mean-square deviation (RMSD) and the
root-mean-square ﬂuctuations (RMSFs) over the backbone
Figure 2. Molecular dynamics simulation of NS2B-NS3 protease with HCQ. (A) Interaction between HCQ and protease active site shows the
greatest stability around 1.5−1.8 Å throughout the simulation period. (B) Protease attains increased stability upon addition of HCQ. (C) HCQ
maintains compactness during the simulation period. (D) NS2B-NS3 protease−HCQ complex shows no loss of hydrogen bonds. [5LC0: NS2B-
NS3 protease; ps: picosecond; residues 49−87 of NS2B are denoted 49−87, while residues 15−167 of NS3 protease are denoted 1015−1167].
ACS Omega Article
DOI: 10.1021/acsomega.8b01002
ACS Omega 2018, 3, 18132−18141
18134
atoms of NS2B-NS3 protease, which includes a series of
carbon, nitrogen, and oxygen. The RMSD plot revealed that
the compound HCQ (Figure 2A) and mitoxantrone (Figure
S3A) demonstrate greatest stability at approximately 1.5−1.8
Å, indicating that the interaction between HCQ and the active
site of the protease is stable throughout the simulation period
of 30 000 ps. The other compounds were observed to have
stability around RMSD of 1.5−2 Å over the simulation time
period (Figure S3). The root-mean-square ﬂuctuations
(RMSFs) illustrate the distinction between the NS2B and
NS3 components of the ZIKV protease (Figures 2 and S3).
HCQ (Figure 2B) and mitoxantrone (Figure S3B) exhibit
the least ﬂuctuation and are associated with the greatest gain in
stability upon binding to NS2B-NS3 protease. Similar RMSFs
are observed at residues 50−100 of the NS3 protease in the
case of all of the compounds, and this may be due to a change
in the interacting residues. Further, the radius of gyration
(Figure 2C) reveals that bound HCQ maintains compactness
during the simulation period. The complex does not lose
hydrogen bonds during the simulation period. HCQ (Figure
2D) and mitoxantrone (Figure S3D) show no loss of hydrogen
bonds throughout the simulation, and the H-bond interactions
were maintained during the simulation period. Overall, the
drug−protease complexes show signiﬁcant stability throughout
the simulation, but compared to other compounds, HCQ and
mitoxantrone show the greatest stability over the 30 000 ps
time scale.
HCQ Inhibits NS2B-NS3 Protease Activity. Among the
top-hit compounds, we selected HCQ, an antimalarial agent
that is considered an FDA Pregnancy Class C drug, for further
investigation. HCQ is also utilized as a chronic suppressive
treatment for rheumatological diseases, such as systemic lupus
erythematosus (SLE).
Importantly, women taking HCQ for SLE are recommended
to continue their HCQ regimen throughout pregnancy, and
several studies illustrate the relative safety of using this drug
Figure 3. HCQ inhibits NS2B-NS3 protease activity. (A) Substrate−velocity curve and (B) Lineweaver−Burk (LB) plot illustrating the activity of
NS2B-NS3 protease (5 nM) with 1.56, 3.125, 6.25, 12.50, 25, 50, 100, and 200 μM substrate benzoyl−norleucine−lysine−lysine−arginine−7-
amino-4-methylcoumarin (benzoyl−Nle−KKR−AMC). (C, D) Inhibition of NS2B-NS3 protease activity by HCQ. NS2B-NS3 protease (5 nM)
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during pregnancy, for both the mother and the developing
fetus.36−38 A recent report on ZIKV transmission in pregnant
mice revealed that HCQ successfully inhibits maternal−fetal
transmission due to modulation of the autophagy pathway in
the placenta.34 HCQ also acts as a potential inhibitor of
dengue virus infection by activating the innate immune
signaling pathway.35 With these features in mind, HCQ was
considered to be a prime candidate for further experiments.
Therefore, we pursued further studies with HCQ and showed
that HCQ likely targets the active site of NS2B-NS3 protease.
The kinetic parameters (Km, kcat, and kcat/Km) of active NS2B-
NS3 protease were obtained using the Michaelis−Menten
equation, which showed Km, kcat, and kcat/Km to be 13.14 ±
1.702 μM, 0.9682 ± 0.0345 min−1, and 0.0737 ± 0.00989
min−1 μM−1, respectively (Figure 3A, B). To demonstrate the
inhibitory potential of the drug against NS2B-NS3 protease,
we computed kinetic parameters in the presence of HCQ
(Figure 3C, D). Using the substrate−velocity curves, we
determined the inhibition constant (Ki) of HCQ to be 92.34 ±
11.91 μM.
HCQ Inhibits ZIKV Burden in Placental Trophoblast
Cells. Given that ZIKV is transmitted from mother to the
developing fetus in a transplacental manner by damaging and
killing placental cells (trophoblasts), we tested the ability of
HCQ to block ZIKV activity in a placental trophoblast cell
line, JEG3. A dose curve of HCQ (0−80 μM) was performed
(data not shown). JEG3 cells were infected for 48 h with ZIKV
and treated with 80 μM HCQ, which led to a highly signiﬁcant
reduction in ZIKV titers (Figure 4A). Next, we examined the
localization of the inhibitory activity of HCQ. Immunoﬂuor-
escence analysis of ZIKV-infected trophoblasts reveals that the
virus can be found in large foci of cells and that HCQ
treatment reduces the number of foci as well as the size of the
foci of infected cells (Figure 4B).
■ DISCUSSION
The rapid spread of ZIKV infection, its association with
microcephaly and neurological disorders,1−4 and its capacity
for human-to-human transmission39,40 have produced an
urgent need for an eﬀective drug against ZIKV. In the area
of drug discovery, repurposing is an eﬃcient approach to
screen drug molecules from an existing drug library for
successful inhibition of a new target,30 and in silico drug
modeling is a useful and cost-eﬀective strategy to identify drug
candidates in a short period. Viral proteases are considered
excellent targets for the identiﬁcation of potential drug
candidates, as protease plays an indispensable role in viral
replication.23−25 This has been the case in human
immunodeﬁciency virus (HIV) research, which has developed
several drugs with the ability to inhibit the HIV protease.41,42
Recently, NS2B-NS3 protease has been investigated as a target
to identify potential inhibitors against other ﬂavivi-
ruses.26−28,43−45 In our study, we have used ZIKV NS2B-
NS3 protease as a target as it plays a key role in processing a
single polyprotein precursor into functional proteins. There-
fore, NS2B-NS3 protease is an attractive target for identifying
potential drug candidates against ZIKV.46,47
A previous report showed signiﬁcant inhibition of the ZIKV
NS2B-NS3 protease by dipeptide boronic acid;13 hence, the
same active site can be utilized to broaden drug discovery
research to develop new therapeutic interventions. To explore
potential new inhibitors of the ZIKV NS2B-NS3 protease, we
employed molecular docking and molecular dynamics
simulation studies of FDA-approved drug molecules. Among
the top hit, we selected HCQ, an antimalarial and
antirheumatic agent that is considered an FDA Pregnancy
Class C drug, for further investigation. We identify a possible
interaction of HCQ with the NS2B-NS3 protease, where the
interactions of certain key amino acid residues of NS2B and
NS3 protease are required to stabilize HCQ at the binding site.
Molecular docking reveals that HCQ exhibits considerable
aﬃnity for the NS2B-NS3 protease active site. Also, reﬁnement
in the binding aﬃnity through induced ﬁt docking conﬁrms
strong binding of HCQ to NS2B-NS3 protease. The binding
and stabilization of HCQ at the active site of NS2B-NS3
protease requires the formation of an H-bond with Asp83 of
NS2B and Gly151 of NS3 protease, a pi interaction at Tyr161,
and a salt bridge at Asp129 of NS3 protease. A similar mode of
interaction has been seen in the NS2B-NS3 protease of Zika
virus, where the substrate interacts through Asp129, Gly151,
and Tyr161 of NS3 protease and Asp83 of NS2B.48 Also, there
are some reports on the NS2B-NS3 protease of Zika virus and
West Nile virus, which demonstrated that a dipeptide boronic
acid compound (cn-716) acts as a reversible inhibitor of the
NS2B-NS3 protease complex.13,49 In the case of Zika virus
protease complex, arginine of cn-716 forms a salt bridge with
Asp129 residue of the NS3 protease, and this feature is
conserved in other ﬂavivirus protease complexes. A similar kind
Figure 4. HCQ treatment reduces ZIKV viral burden in placental cells. (A) Titers at 48 h post infection (hpi) of ZIKV-infected JEG3 cells treated
with indicated concentrations of HCQ. Symbols represent six biological replicates from two separate experiments. The bars represent mean ±
standard error of the mean. *P < 0.01 (Mann−Whitney test). (B) Representative immunoﬂuorescence microscopy for ZIKV-E protein-positive
(green) cells following indicated treatments. Nuclei are stained blue.
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of interaction has also been seen in the crystal structure of
West Nile virus NS3 protease complexed with an inhibitor.50,51
This interaction provides a basis for the strong binding
hypothesized between HCQ and the active site of NS2B-NS3
protease. Also, our molecular dynamics simulation result shows
the stabilization of the HCQ at the active site of NS2B-NS3
protease throughout simulation period. Further, enzyme
inhibition kinetics suggest that HCQ signiﬁcantly inhibits the
activity of NS2B-NS3 protease (Ki = 92.34 ± 11.91 μM). Here,
we show that HCQ blocks ZIKV protease activity. On the
basis of the previous report on chloroquine inhibiting
proteolytic processing of prM to M protein,52 we do not rule
out the possibility of other targets of HCQ in Zika virus, but
these need to be further explored. Previous studies
documented the antiviral properties of chloroquine and
HCQ. They suggested that chloroquine inhibits the early
and late stages of viral replication, but the antiviral eﬀect of the
drug is increased when added before infection compared to
post infection.53 From these studies, it is clear that at early
stages of viral replication, chloroquine acts as an entry
inhibitor. In our studies, we treated the trophoblast cells
with HCQ 3 h post infection (hpi); therefore, reduced viral
burden may have resulted due to inhibition of late-stage viral
replication such as the inhibition of viral particle maturation.
HCQ may be inhibiting the maturation of polyprotein by
blocking NS2B-NS3 protease activity. Since NS2B-NS3
protease plays an important role in the proteolytic processing
of ZIKV polyprotein, we can hypothesize that blocking
protease activity with HCQ will inhibit polyprotein processing
and subsequent viral assembly and maturation. In our recent
report on ZIKV transmission in pregnant mice, we revealed
that HCQ successfully inhibits maternal−fetal transmission
due to modulation of the autophagy pathway in the placenta.34
Our study demonstrates that HCQ can additionally inhibit
ZIKV infection of placental trophoblasts possibly due to its
binding aﬃnity to the ZIKV NS2B-NS3 protease.
The ﬁve other top-ranked compounds, viz., mitoxantrone,
miglustat, nadolol, carteolol, and pindolol, form stable
interactions with the amino acid residues of NS2B and NS3
protease at the active site. The residues Asp129, Ser135,
Gly153, and Tyr161 of NS3 protease and Asp83 of NS2B are
involved in establishing the HCQ interaction, demonstrating a
similar mode of interaction between substrate/inhibitor as seen
in other ﬂavivirus proteases.50,51,54 In summary, various amino
acid residues are involved in stabilizing drug molecules at the
active site of the NS2B-NS3 protease of Zika virus. Further
studies will test the other top compounds for their inhibitory
eﬀect against Zika virus.
■ METHODS
System Conﬁguration. Molecular docking and molecular
dynamics simulation studies were executed using a high-
performance GPU operated with CentOS V6.6 Linux
operating platform and with hardware conﬁguration of the
HPC GPU Super Micro Intel Xeon E5-620 v3 series with 8-
core processor, 64 GB DDR4-2133 ECC RDIMM of RAM,
and graphics card of NvidiaQuadroK2000 with 2 GB. The
software speciﬁcations we used for docking and molecular
dynamics simulation are the commercial version of Schrö-
dinger software package, LLC, NY 2012, and the all-atom
optimized potentials for liquid simulations (OPLS-AA) force
ﬁeld academic-licensed molecular dynamics package of
Desmond4.4.
Structure-Based Virtual Screening. The X-ray crystal
structure of the NS2B-NS3 protease (PDB ID: 5LC0) was
retrieved from the Protein Data Bank. The crystal structure of
NS2B-NS3 protease (dimer form, chains A and B) is
crystallized with dipeptide boronic acid (cn-716; ID: 6T8),
where each monomer contains a cn-716. The dipeptide
boronic acid acts as an inhibitor, embedded at the substrate
binding site of the protease. Each monomeric unit comprises a
C-terminal fragment of NS2B (hydrophilic residues 49−95),
fused via a linker (Gly)4−Ser−(Gly)4 with the N-terminus of
NS3.13 The NS2B-NS3 protease monomer was prepared using
the Schrödinger suite protein preparation wizard, which has
two main functions: preparation and reﬁnement. These
features of the preparation wizard perform various tasks, viz.,
assigning a bond order, adding hydrogen, creating zero-order
bonds to metals, creating disulﬁde bonds, ﬁlling in missing side
chains, and removing water molecules beyond 5 Å. Further
structural optimization was done at pH 7, and water molecules
with fewer than three H-bonds were removed. The embedded
dipeptide boronic acid compound has been used as a model to
investigate catalytic drug binding. This site was chosen as a
prerequisite for receptor grid generation to protease using the
Grid generation panel of the Schrödinger suite Glide Module.
We used boronate inhibitor as a reference to create the size of
the grid (X-, Y-, and Z-coordinates as 81.82, 51.89, and 153.80
Å, respectively), where the incoming ligand binds during the
docking process. Receptor grid scaling of van der Waals radii of
receptor atoms was done with a scaling factor of one unit and a
partial charge cutoﬀ of 0.25 to soften the potential of nonpolar
parts of the receptor. The FDA-approved drug compounds
were prepared using the Schrödinger suite Ligand Prep module
before they underwent ligand docking. This drug library,
consisting of 1861 compounds, was selected from the
DrugBank database.55 The Ligand Prep module is able to
generate diﬀerent structures of compounds based on stereo-
isomers, ring conformations, and ionization states for each
processed compound. Ligand preparation of 1861 drug
compounds produced 5323 structures that were processed
through the Lipinski ﬁlter (retaining structures with molecular
weights ≤500 g/mol to make the screening more eﬀective and
to retrieve the compounds that satisfy all conditions of
ﬁltration) and a reactive ﬁlter. Out of 5323 structures, 2558
passed through the Lipinski and reactive ﬁlters. To screen a
potential candidate for inhibition, FDA-approved drugs were
processed using a Glide program. These drug compounds were
docked at the active site of NS2B-NS3 protease and ﬁltered
using high-throughput virtual screening (HTVS), standard
precision (SP), and extra precision (XP) docking. First, we
performed high-throughput virtual screening (HTVS), which
rapidly identiﬁed the top 40% of input compounds based on
docking score. These selected molecules then underwent
standard precision (SP) docking at the same active site on the
protease, again eliminating all but the top 40% of input
compounds. The next phase, extra precision (XP) docking,
selected only the top 10% of the input compounds.
To understand the binding between protease and drug
compounds more accurately, we employed induced ﬁt docking
(IFD). IFD accurately predicts binding poses of ligands to
their receptors and occurrences of structural changes at the
receptor during ligand binding. It involves the Glide module
and Prime module to predict accurate binding, considering the
ﬂexibility of both the ligand and receptor.56 We used a
standard protocol that generates up to 20 poses using
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automatic docking settings. It utilizes a receptor van der Waals
scaling of 0.50 and a ligand van der Waals scaling of 0.05, and
it penalizes nonpolar conformations for amide bonds and
sample ring conformations with 2.5 kcal/mol energy windows.
Further reﬁnement was done for residues within 5 Å of ligand
poses. Glide redocking into structures within 30 kcal/mol of
the best structure and within the top 20 structures overall was
performed with XP precision. Among diﬀerent poses and
conformations, the best one was selected based on docking
score.
Molecular Dynamics (MD) Simulation. The NS2B-NS3
protease−ligand complex was subjected to a 30 ns molecular
dynamics simulation to further evaluate their stability. The
intramolecular conformational changes that occur in the
protein structure have been well explained by molecular
dynamics simulation studies.57 Molecular dynamics of the
NS2B-NS3 protease−FDA drug complexes were simulated
using the Desmond module of Schrödinger package.58 The
docking score and the interaction analysis were used to select
compounds that would be carried forward to the energy
minimization and molecular dynamics simulation studies with
the OPLS-AA force ﬁeld.59 An orthorhombic water box was
created using the Desmond system builder, and preequilibrated
TIP3P water molecules and 0.15 M Na + Cl− were placed in
the system as neutralizing compounds.60 A distance of greater
than 5 Å was maintained between the box wall and protein,
thereby ensuring that the protein could not directly interact
with its own periodic image. Energy minimization of the
protein complex in the prepared system for MD simulation was
carried out to a maximum of 3000 steps using the steepest
descent until a gradient threshold (25 kcal/(mol Å)) was
reached. The periodic boundary conditions were applied, and
the long-range electrostatic interactions were treated with
Ewald sums.61 The molecular dynamics simulation was
performed at a constant temperature of 300 K and a pressure
of 1.01 bar with a time interval of 2 fs.62,63 A cutoﬀ radius of 9
Å was selected for the coulombic short-range interaction cutoﬀ
method. At every 4.8 ps, the frames of the trajectory were
captured. The root-mean-square deviation (RMSD) and root-
mean-square ﬂuctuation (RMSF) of the backbone were
obtained through the simulation using the ﬁrst frames as a
reference.61
Gene Construct and Protein Puriﬁcation. We chose an
expression plasmid vector, pET151/D-T, to insert a DNA
fragment encoding NS2B-NS3 protease of ZIKV. An
Escherichia coli codon-optimized DNA sequence encoding
NS2B-NS3 protease (amino acid sequence taken from NS2B-
NS3 protease structure 5LC0 from the Protein Data Bank) was
inserted in the vector in-frame with 6XHis tag and TEV
cleavage site (synthesized by Invitrogen). Restriction enzymes
XhoI and NdeI were used to insert the gene of interest into the
vector. The NS2B-NS3 protease gene (with tag, i.e., 6Xhis-V5
epitope−TEV cleavage site) is composed of 263 residues, and
it has a molecular weight and a theoretical isoelectric point of
27.99 kDa and 5.40, respectively, as determined by the ExPASy
ProtParam tool. This recombinant plasmid encodes a
polypeptide whose sequence from N- to C-terminus reads:
6Xhis-V5 epitope−TEV cleavage site−NS2B-NS3 protease
gene. Transformation of recombinant plasmid was done in
BL21(DE3) E. coli cells, and cells positive for the recombinant
plasmid were used to express NS2B-NS3 protease (in LB
media and 0.5 mM IPTG at 20 °C for 16 h). The cells were
harvested by centrifugation (6000 rpm, 10 min) at 4 °C.
Afterward, cell lysis was done using B-PER (Thermo Fisher
Scientiﬁc) and phenylmethylsulfonyl ﬂuoride (1 mM) at 4 °C
(30 min incubation). The NS2B-NS3 protease was puriﬁed
from the soluble fraction through HisPur Cobalt Resin
(Thermo Fisher Scientiﬁc) using Tris−HCl binding buﬀer
(25 mM Tris−HCl, 300 mM NaCl, 40 mM imidazole, and
10% glycerol, pH 8.5) and elution buﬀer (25 mM Tris−HCl,
300 mM NaCl, 500 mM imidazole, and 10% glycerol, pH 8.5).
Next, the tag of the puriﬁed NS2B-NS3 protease was removed
by tobacco etch virus protease (AcTEV, Invitrogen) while
incubating at 25 °C for 4.5 h. Hydrolysis by AcTEV produced
a polypeptide of 236 residues (24.837 kDa), where 230
residues are from the NS2B-NS3 protease reported as 5LC0,13
and the remaining six residues (at the N-terminus of the
polypeptide) are Gly−Ile−Asp−Pro−Phe−Thr. The cleaved
NS2B-NS3 protease was puriﬁed through HisPur Cobalt Resin
using 25 mM Tris−HCl, pH 8.5 containing 10% glycerol. The
purity of NS2B-NS3 protease (uncleaved and cleaved) was
analyzed with sodium dodecyl sulfate polyacrylamide gel
electrophoresis (12%).
Activity Assay. Enzyme kinetics of the NS2B-NS3 protease
was determined in a reaction buﬀer containing 10 mM
phosphate, 1 mM TCEP, 1 mM CHAPS, and 20% glycerol, pH
7 and 30 °C. In a 96-well black plate, the substrate, benzoyl−
norleucine−lysine−lysine−arginine−7-amino-4-methylcou-
marin (benzoyl−Nle−KKR−AMC; Sigma-Aldrich: 98.6%
purity; stock preparation: in water), was serially diluted in
reaction buﬀer (10 mM phosphate buﬀer, 1 mM TCEP, 1 mM
CHAPS, and 20% glycerol; pH 7) to achieve a concentration
range of 1.56−200 μM. Afterward, NS2B-NS3 protease was
added into the wells to a 5 nM ﬁnal concentration. The
ﬂuorescence signal of released AMC was monitored with an
emission wavelength of 460 nm at 360 nm excitation using a
multiplate reader (inﬁniteM200PRO: TECAN), while gain was
adjusted manually to 80. The amount of released AMC at
varying substrate concentrations was determined via a standard
curve of ﬂuorescence signal produced as a function of free
AMC (concentration range: 0.025−12.8 μM; stock: 50 mM in
100% dimethyl sulfoxide). Further, the initial velocity of the
reaction was calculated in terms of the amount of AMC
produced per minute during 15 min. The data were ﬁtted to
the Michaelis−Menten equation, V = Vmax[S]/(Km + [S]), to
determine enzyme kinetic parameters (Km, kcat, and Vmax) using
GraphPad Prism 7.0 software. Measurement of data points was
taken in triplicates, and data were represented as a mean ±
standard error with R2 = 0.95.
Inhibition Assay. For inhibition studies, to determine the
enzyme kinetic parameters, we used the same reaction buﬀer
and substrate as we used to determine the activity of the
NS2B-NS3 protease. HCQ (Sigma-Aldrich) was dissolved in
water to prepare 50 mM stock solutions, which were serially
diluted in reaction buﬀer to make a variable range of
concentrations (0, 12.5, 25, 100, and 200 μM). Subsequently,
NS2B-NS3 protease (5 nM ﬁnal concentration for 50 μl
reaction volume) was mixed with diﬀerent concentrations of
HCQ and incubated for 10 min at 30 °C. Afterward, the
reaction was initiated by adding 25 μl of substrate (to ﬁnal
substrate concentrations of 3.125, 6.25, 12.5, 25, 50, and 100
μM). The ﬂuorescence signal was monitored at 460 nm
emission and 360 nm excitation wavelength at every 5 min of
interval. Further, the Ki was computed using GraphPad Prism
7.0 software at 15 min. Experiments were set up in triplicate,
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and values were represented as a mean ± standard error with
R2 = 0.95.
ZIKV Infection and Measurement of Viral Burden in
Vitro. The Brazilian strain of ZIKV (Paraiba 2015) was used
in this study.64 Studies with ZIKV were conducted under
biosafety level 2 (BSL2). JEG3, a human cytotrophoblast cell
line from the ATCC (HTB-36), was cultured in Dulbecco’s
modiﬁed Eagle’s medium supplemented with 10% fetal bovine
serum (Thermo Fisher Scientiﬁc) at 37 °C with 5% CO2. JEG3
cells were infected with ZIKV at a multiplicity of infection of
0.1 for 3 h, washed twice with warm phosphate-buﬀered saline,
and then cultured in fresh media containing 0 or 80 μM
hydroxychloroquine (Sigma-Aldrich). At 48 h post infection
(hpi), the cells were harvested for the measurement of viral
burden or were ﬁxed for immunoﬂuorescence using a ZIKV-
speciﬁc mAb, ZV-2, as previously described.64 After 48 h,
supernatants were harvested for RNA extraction using the Viral
RNA Mini kit (Qiagen). ZIKV RNA levels were determined by
one-step quantitative reverse transcriptase polymerase chain
reaction on an ABI 7500 Fast Instrument using standard
cycling conditions. Viral burden from supernatant samples was
expressed on a log10 scale as viral RNA equivalents per mL
after comparison with a standard curve produced using serial
10-fold dilutions of ZIKV RNA. A published primer set was





For immunoﬂuorescence studies, the cells were grown on
Millicell EZ slides (Millipore Sigma), ﬁxed with 4%
paraformaldehyde, and permeabilized with 0.3% Triton X.
After blocking with 1% bovine serum albumin, the cells were
incubated overnight with primary antibodies to the E protein
of ZIKV,64 followed by ﬂuorescently labeled secondary
antibodies (Thermo Fisher Scientiﬁc). Images were obtained
using a Zeiss LSM880 Confocal Laser Scanning Microscope
with Airyscan. Images were processed and analyzed using
Adobe Photoshop and NIH Image J software.
GraphPad Prism 5.0 was used for all cell culture-related
analyses. The analyses of virologic data were conducted using a
Mann−Whitney test. Data with p-values <0.05 were
considered to be statistically signiﬁcant.
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